Company & Sponsor Intelligence
H. Lundbeck A/S
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials13
Recruiting2
Completed6
Countries4
Therapeutic footprint
alzheimersdepressionmigraine_headachepain_neuropathyparkinsonsschizophrenia
Indexed studies
NCT06323928A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
migraine_headache · United StatesPHASE2
migraine_headache · United StatesPHASE2
NCT03555136Real-life Effectiveness of Vortioxetine in Depression
depression · United StatesCOMPLETED
depression · United StatesCOMPLETED
NCT01323478Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
depression · PHASE3
depression · PHASE3
NCT03668405A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)
alzheimers · FinlandPHASE1
alzheimers · FinlandPHASE1
NCT07514858A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT02709655Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT05897320A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
migraine_headache · United StatesPHASE3
migraine_headache · United StatesPHASE3
NCT04974359A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
pain_neuropathy · United StatesPHASE1
pain_neuropathy · United StatesPHASE1
NCT03793712Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
schizophrenia · BulgariaPHASE2
schizophrenia · BulgariaPHASE2
NCT02649608An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
NCT03819699Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD
alzheimers · FinlandPHASE1
alzheimers · FinlandPHASE1
NCT04294654Vortioxetine in Patients With Depression and Early Dementia
depression · EstoniaPHASE4
depression · EstoniaPHASE4
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →